3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
16
Rectal Neoplasms
4
Colonic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Neoplasms
2
Biliary Tract Neoplasms
2
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Metastatic Gastric Adenocarcinoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Desmoid Tumors
1
Craniopharyngioma
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced/Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Adenomatous Polyposis Coli
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
10
pembrolizumab
8
Fluorouracil
8
Leucovorin
7
Paclitaxel
5
Gemcitabine
5
Docetaxel
5
Capecitabine
5
Cyclophosphamide
4
Blood Specimen Collection
4
zolbetuximab
3
fludarabine
3
darolutamide
3
cemiplimab
3
Trastuzumab
3
Taxes
3
Ramucirumab
3
Radiotherapy
3
Radiosurgery
3
Irinotecan
3
trastuzumab deruxtecan
2
enzalutamide
2
durvalumab
2
Standard of Care
2
Nivolumab
2
Folfox protocol
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma
×
trifluridine tipiracil drug combination
×
Clear all
NCT05476796
2024-10-24
LOGICAN
UNICANCER
Phase 2
Recruiting
118 enrolled